LOUISVILLE, Colo., Oct. 9 Replidyne, Inc.(Nasdaq: RDYN) announced today that it will host a conference call and webcaston Tuesday, October 30, 2007 at 4:45 P.M. EDT to report third quarter 2007earnings. Callers may participate in the conference call by dialing800-435-1261 (domestic) or 617-614-4076 (international), and providing thepasscode 57078639.
A replay of the conference call will be available approximately one hourafter completion of the call through Tuesday, November 13, 2007 at midnight.Callers may access the replay by dialing 888-286-8010 (U.S. participants) or617-801-6888 (international participants). The audio replay passcode is69926592. To access a replay of the webcast, visit the Investor Relationssection of the company's website at http://www.Replidyne.com.
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering,developing, in-licensing and commercializing innovative anti-infectiveproducts. Replidyne's lead product, faropenem medoxomil, is a novel oralcommunity antibiotic, expected to be appropriate for use as a first-lineantibiotic for treatment of respiratory and skin infections in adult andpediatric patients. Replidyne's second drug candidate, REP8839, is a topicalanti-infective product candidate in development for the treatment of skin andwound infections, including methicillin-resistant S. aureus (MRSA) infections.Replidyne's investigational antibacterial agent REP3123 targets Gram-positiveC. difficile bacteria and C. difficile-associated disease (CDAD). Replidyneis pursuing the development of other novel anti-infective programs based onits in-house discovery research.
This press release contains plans, intentions, objectives, estimates andexpectations that constitute forward-looking statements about Replidyne, Inc.that involve significant risks and uncertainties. Actual results could differmaterially from those discussed due to a number of factors including, thesuccess and timing of pre-clinical studies and clinical trials; the Company'sability to obtain a new partner for faropenem on acceptable terms; theCompany's ability to obtain and maintain regulatory approval of productcandidates and the labeling under any approval that may be obtained; plans todevelop and commercialize product candidates; the loss of key scientific ormanagement personnel; the size and growth of the potential markets for theCompany's product candidates and the Company's ability to serve thosemarkets; regulatory developments in the U.S. and foreign countries; the rateand degree of market acceptance of any future products; the accuracy ofCompany estimates regarding expenses, future revenues and capitalrequirements; the Company's ability to obtain and maintain intellectualproperty protection for our product candidates; the successful development ofthe Company's sales and marketing capabilities; the success of competing drugsthat are or become available; and the performance of third party manufacturers.These and additional risks and uncertainties are described more fully in theCompany's most recent Form 10-Q filed with the SEC under the SecuritiesExchange Act of 1934. Copies of filings made with the SEC are availablethrough the SEC's electronic data gather analysis and retrieval system (EDGAR)at http://www.sec.gov. All forward-looking statements made in the pressrelease are made as of the date hereof and the Company assumes no obligationto update the forward-looking statements in the document.
SOURCE Replidyne, Inc.